ofloxacin has been researched along with Pneumonia in 104 studies
Ofloxacin: A synthetic fluoroquinolone antibacterial agent that inhibits the supercoiling activity of bacterial DNA GYRASE, halting DNA REPLICATION.
9-fluoro-3-methyl-10-(4-methylpiperazin-1-yl)-7-oxo-2,3-dihydro-7H-[1,4]oxazino[2,3,4-ij]quinoline-6-carboxylic acid : An oxazinoquinoline that is 2,3-dihydro-7H-[1,4]oxazino[2,3,4-ij]quinolin-7-one substituted by methyl, carboxy, fluoro, and 4-methylpiperazin-1-yl groups at positions 3, 6, 9, and 10, respectively.
ofloxacin : A racemate comprising equimolar amounts of levofloxacin and dextrofloxacin. It is a synthetic fluoroquinolone antibacterial agent which inhibits the supercoiling activity of bacterial DNA gyrase, halting DNA replication.
Pneumonia: Infection of the lung often accompanied by inflammation.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Nemonoxacin, a novel nonfluorinated quinolone, exhibits potent in vitro and in vivo activities against community-acquired pneumonia (CAP) pathogens, including multidrug-resistant Streptococcus pneumoniae." | 9.14 | Efficacy and safety of nemonoxacin versus levofloxacin for community-acquired pneumonia. ( Bester, AJ; Chang, LW; Chang, YT; Chung, DT; Ho, ML; Hsu, MC; Kasumba, J; King, CH; Mitha, IH; Perng, RP; van Rensburg, DJ; Wu, RG, 2010) |
| "Levofloxacin has established efficacy and safety in the treatment of community-acquired pneumonia (CAP) in adults, and its use as an alternative therapy for children with CAP has been proposed." | 9.12 | Comparative study of levofloxacin in the treatment of children with community-acquired pneumonia. ( Arguedas, A; Blumer, JL; Bradley, JS; Melkote, R; Noel, GJ; Sáez-Llorens, X, 2007) |
| "In this study, we analyzed 302 patients with pneumonia admitted to the Intensive Care Unit (ICU) who were treated with levofloxacin (LFX) either as monotherapy or combined therapy." | 9.11 | Levofloxacin in the treatment of pneumonia in intensive care unit patients. ( Alvarez-Lerma, F; Bermejo, B; León, C; Olaechea, P; Palomar, M; Sanchez, M, 2004) |
| "0-g oral dose of a novel microsphere formulation of azithromycin was at least as effective as 7 days of levofloxacin, 500 mg/day, in the treatment of adult patients with mild to moderate community-acquired pneumonia (Fine classes I, II, and III)." | 9.11 | Novel, single-dose microsphere formulation of azithromycin versus 7-day levofloxacin therapy for treatment of mild to moderate community-acquired Pneumonia in adults. ( Breen, JD; Camere, MA; D'Ignazio, J; Jorgensen, D; Lewis, DE, 2005) |
| "This subgroup analysis sought to determine the efficacy and tolerability of a 5-day regimen of levofloxacin 750 mg/d compared with a 10-day regimen of levofloxacin 500 mg/d in the treatment of community-acquired pneumonia (CAP) in elderly patients (aged > or =65 years)." | 9.11 | A multicenter, randomized, double-blind, retrospective comparison of 5- and 10-day regimens of levofloxacin in a subgroup of patients aged > or =65 years with community-acquired pneumonia. ( Shorr, AF; Tennenberg, AM; Wes Ely, E; Xiang, JX; Zadeikis, N, 2005) |
| "Levofloxacin, an antibiotic from the quinolone family, which is used with success in the ambulatory treatment of patients with community-acquired pneumonia, has been recently introduced to the pharmaceutical market." | 9.09 | [Oral levofloxacin versus intravenous ceftriaxone and amoxicillin/clavulanic acid in the treatment of community-acquired pneumonia that requires hospitalization]. ( Bagilet, D; Diab, M; Javkin, E; Kalbermatter, V, 2000) |
| "An exclusively oral regimen, in this case ofloxacin, may be substituted for parenteral therapy in selected patients with pneumonia." | 9.07 | Oral ofloxacin for the treatment of acute bacterial pneumonia: use of a nontraditional protocol to compare experimental therapy with "usual care" in a multicenter clinical trial. ( Alessi, P; Bittner, MJ; Iannini, P; Makris, AT; McCloskey, RV; Morris, JF; Sanders, WE; Trenholme, GM, 1991) |
| "Our study of 28 carefully selected patients proved that ofloxacin is a safe and effective drug for mild to moderately severe community-acquired pneumonia." | 9.07 | Treatment of community-acquired pneumonia with ofloxacin. ( Charoenratanakul, S; Nana, A; Permpikul, C; Thamlikitkul, V; Youngchaiyud, P, 1991) |
| "Limited data suggest that tetracycline or erythromycin is the antibiotic of choice for treating Chlamydia pneumoniae infection, but they are not always effective or well tolerated." | 9.06 | Ofloxacin treatment of Chlamydia pneumoniae (strain TWAR) lower respiratory tract infections. ( Grayston, JT; Kuo, CC; Lipsky, BA; Tack, KJ; Wang, SP, 1990) |
| "A randomized, open, prospective study including 45 patients with either soft tissue infections (29 cases) or pneumonia (15 cases) after surgical intervention and one case having both indications was carried out with ofloxacin." | 9.06 | Treatment of surgical infections with a modern quinolone: therapy of soft tissue infections and pneumonia with ofloxacin. ( Fritzen, T; Marx, E; Uy, J, 1986) |
| "In an open clinical trial, out-patients with respiratory tract infections were given 200 mg ofloxacin b." | 9.06 | [Respiratory tract infections--clinical results with ofloxacin]. ( Knothe, H; Shah, PM, 1986) |
| "The efficacy and tolerance of ofloxacin and doxycycline were compared in patients with lower respiratory tract infections." | 9.06 | An open randomised comparison of ofloxacin and doxycycline in lower respiratory tract infections. ( Harazim, H; Mittermayer, HP; Wimmer, J, 1987) |
| "We describe four patients who had seizures while receiving ofloxacin; no other causes were evident." | 8.79 | Seizures associated with ofloxacin therapy. ( Bonfiglio, MF; Martin, BR; Nackes, NA; Traeger, SM; Wilson, JA, 1995) |
| "To evaluate the antibacterial and anti-inflammatory effects of kolaviron on albino Wistar rats induced with pneumonia using Klebsiella pneumonia." | 8.02 | Effects of Kolaviron on Pneumonia-like Infection Induced in Albino Wistar Rats. ( Catherine, OF; Dozie, NC; Dozie-Nwakile, OC; Felicia, ON; Kingsley, UI, 2021) |
| " We present a report of a 65-year-old woman with a bilateral Achilles tendon rupture following use of levofloxacin and corticosteroids for pneumonia." | 7.78 | [Bilateral Achilles tendon rupture following levofloxacin and glucocorticoid use]. ( Bénard, MR; Kok, LM; van Arkel, ER, 2012) |
| "An 83-year-old man was admitted for right lower lobe pneumonia which did not improve after a 5-day outpatient treatment with amoxicillin/clavulinate and clarithromycin." | 7.75 | Levofloxacin-induced delirium. ( Elias, N; Odeh, M; Sabetay, S; Sheikh-Ahmad, M; Slobodin, G; Weller, B; Zaygraikin, N, 2009) |
| "A malnourished 58-year-old man with diabetes developed hypoglycemia after receiving levofloxacin in conjunction with glipizide." | 7.75 | Hypoglycemia associated with the use of levofloxacin. ( Garber, SM; Miller, SM; Pound, MW, 2009) |
| "A pharmacodynamic model was used to generate supportive data comparing tigecycline with other broad-spectrum agents against pathogens implicated in hospital-acquired pneumonia (HAP)." | 7.74 | A pharmacodynamic simulation to assess tigecycline efficacy for hospital-acquired pneumonia compared with other common intravenous antibiotics. ( Dowzicky, M; Kuti, JL; Nicolau, DP, 2008) |
| "We describe the first case of failure of oral levofloxacin treatment of community-acquired pneumonia caused by Haemophilus influenzae." | 7.72 | Levofloxacin treatment failure in Haemophilus influenzae pneumonia. ( Alonso-Tarrés, C; Bastida, T; Campos, J; Cortés-Lletget, MC; de la Campa, AG; Pérez-Vázquez, M; Román, F; Tubau, F, 2003) |
| "THE EFFICACY OF LEVOFLOXACIN: In treating community-acquired pneumonia (CAP) has been assessed during 5 large clinical trials (including 4 controlled randomized trials)." | 7.71 | [Update on the role of levofloxacin in the management of acute community-acquired pneumonia]. ( Bru, JP, 2002) |
| "The aim of this study was to assess the clinical efficacy of a combination of penicillin G and ofloxacin in the treatment of community acquired pneumonia." | 7.68 | [The combination of penicillin G and ofloxacin: a response to the empirical treatment of community acquired pneumonia]. ( Canton, P; Dopff, C; Dureux, JB; Gerard, A; May, T; Mertes, PM; Nace, L; Preiss, MA; Voiriot, P, 1990) |
| "We have compared the efficacy of temafloxacin against Streptococcus pneumoniae in experimental murine pneumonia models with that of ofloxacin and ciprofloxacin." | 7.68 | Comparative activity of fluorinated quinolones in acute and subacute Streptococcus pneumoniae pneumonia models: efficacy of temafloxacin. ( Azoulay-Dupuis, E; Bedos, JP; Pocidalo, JJ; Vallée, E, 1991) |
| "We report a multicentric, open trial of intravenous followed by oral ofloxacin, 400 mg every 12 h, as therapy for 100 cases of nosocomial pneumonia and community-acquired pneumonia requiring hospitalization." | 7.68 | Parenteral followed by oral ofloxacin for nosocomial pneumonia and community-acquired pneumonia requiring hospitalization. ( Gentry, LO; Khan, FA; Kohler, RB; Rodriguez-Gomez, G; Rytel, MW, 1992) |
| "The therapeutic activity of ciprofloxacin, enoxacin, and ofloxacin was evaluated in guinea pigs with acute and chronic experimental Pseudomonas aeruginosa pneumonia." | 7.67 | Comparative evaluation of ciprofloxacin, enoxacin, and ofloxacin in experimental Pseudomonas aeruginosa pneumonia. ( Kemmerich, B; Pennington, JE; Small, GJ, 1986) |
| "A murine model of bacteremic Haemophilus influenzae type b pneumonia was used to evaluate the therapeutic efficacies of the quinolone antimicrobial agents enoxacin and ofloxacin compared with those of ampicillin and chloramphenicol." | 7.67 | Comparative evaluation of enoxacin, ofloxacin, ampicillin, and chloramphenicol for treatment of experimental Haemophilus influenzae pneumonia. ( Borner, K; Kemmerich, B; Pennington, JE, 1987) |
| "The clinical efficacy and the safety of ofloxacin in lower respiratory tract infections were evaluated by 42 research groups in Japan." | 7.67 | Clinical evaluation of ofloxacin in lower respiratory tract infections. ( Kobayashi, H, 1986) |
| "The chemotherapeutic efficacy of ofloxacin against experimental pneumonia was investigated with special reference to its treatment regimen." | 7.67 | Chemotherapeutic efficacy of ofloxacin against experimental pneumonia with Pseudomonas aeruginosa in guinea pigs. ( Hashimoto, S; Iigo, Y; Ishida, Y; Nakajima, R; Osada, Y; Otani, T; Une, T, 1989) |
| "Levofloxacin was as well tolerated as azithromycin, with an incidence of drug-related adverse events (AEs) for all body systems of 5." | 6.70 | A multicenter, open-label, randomized comparison of levofloxacin and azithromycin plus ceftriaxone in hospitalized adults with moderate to severe community-acquired pneumonia. ( Bahal, N; Frank, E; Freitag, S; Kahn, JB; Kinasewitz, G; Liu, J; Moran, GJ; Olson, WH; Oross, MP; Reichl, V; Tennenberg, A; Wiesinger, BA, 2002) |
| "Levofloxacin has been evaluated for the treatment of community-acquired pneumonia (CAP) in numerous randomized clinical trials." | 6.43 | Levofloxacin for the treatment of community-acquired pneumonia. ( File, TM; Lynch, JP; Zhanel, GG, 2006) |
| " Nine patients (2 with liver dysfunction, 6 with renal dysfunction and 1 with thrombocytopenia) out of 62 patients were reported to have possible adverse effects of LVFX." | 5.40 | [Efficacy and safety of levofloxacin in patients with nursing and healthcare-associated pneumonia]. ( Akata, K; Awaya, Y; Chojin, Y; Hara, K; Hata, R; Inoue, N; Ishimoto, H; Kato, K; Kawanami, T; Kawanami, Y; Mukae, H; Naito, K; Nishida, C; Noguchi, S; Obata, H; Oda, K; Ogoshi, T; Orihashi, T; Sasahara, Y; Shimabukuro, I; Shiraishi, T; Suzuki, Y; Tachiwada, T; Takaki, T; Taura, Y; Tokuyama, S; Tsuda, T; Uchimura, K; Yamasaki, K; Yatera, K; Yoshida, Y; Yoshii, C, 2014) |
| "Levofloxacin is a third-generation fluorinated quinolone antibiotic, is the active levo stereoisomer of ofloxacin, and has one of the most favorable adverse reaction profiles." | 5.38 | Levofloxacin-induced delirium: is it a dangerous drug in patients with renal dysfunction? ( Dortdudak, S; Eroglu, E; Kocyigit, I; Oymak, O; Sipahioglu, M; Tokgoz, B; Unal, A; Utas, C; Yucel, HE, 2012) |
| "Levofloxacin was administered and 3 days later, he complained of pain in the left Achilles tendon and revealed redness and swelling in the area." | 5.36 | Levofloxacin-induced Achilles tendinitis in a young adult in the absence of predisposing conditions. ( Baek, YS; Cheong, MH; Durey, A; Lee, JS; Lee, K; Park, JS; Ryu, JS, 2010) |
| " Average length of stay (LOS), hospital costs, death rate, age, and ratio of oral to intravenous dosage administration were analyzed." | 5.31 | Experiences at a large teaching hospital with levofloxacin for the treatment of community-acquired pneumonia. ( Clark, LC; Davis, CW, 2000) |
| "The ofloxacin MICs were inoculum dependent and ranged from 0." | 5.27 | Susceptibility of Legionella pneumophila to ofloxacin in vitro and in experimental Legionella pneumonia in guinea pigs. ( Fujita, K; Fukuda, Y; Koga, H; Nagasawa, M; Nakazato, H; Saito, A; Sawatari, K; Shigeno, Y; Suzuyama, Y; Tomonaga, A, 1985) |
| "An analysis of subjects with concurrent bacteraemia and either nosocomial pneumonia, complicated intra-abdominal infection or complicated urinary tract infection from six phase 3 clinical trials demonstrated similar cure rates and clearance of bacteraemia in patients treated with doripenem and comparator agents." | 5.17 | Activity of doripenem versus comparators in subjects with baseline bacteraemia in six pooled phase 3 clinical trials. ( Kaniga, K; Lee, M; Redman, R; Rice, DA, 2013) |
| "Nemonoxacin, a novel nonfluorinated quinolone, exhibits potent in vitro and in vivo activities against community-acquired pneumonia (CAP) pathogens, including multidrug-resistant Streptococcus pneumoniae." | 5.14 | Efficacy and safety of nemonoxacin versus levofloxacin for community-acquired pneumonia. ( Bester, AJ; Chang, LW; Chang, YT; Chung, DT; Ho, ML; Hsu, MC; Kasumba, J; King, CH; Mitha, IH; Perng, RP; van Rensburg, DJ; Wu, RG, 2010) |
| "Levofloxacin has established efficacy and safety in the treatment of community-acquired pneumonia (CAP) in adults, and its use as an alternative therapy for children with CAP has been proposed." | 5.12 | Comparative study of levofloxacin in the treatment of children with community-acquired pneumonia. ( Arguedas, A; Blumer, JL; Bradley, JS; Melkote, R; Noel, GJ; Sáez-Llorens, X, 2007) |
| "0-g oral dose of a novel microsphere formulation of azithromycin was at least as effective as 7 days of levofloxacin, 500 mg/day, in the treatment of adult patients with mild to moderate community-acquired pneumonia (Fine classes I, II, and III)." | 5.11 | Novel, single-dose microsphere formulation of azithromycin versus 7-day levofloxacin therapy for treatment of mild to moderate community-acquired Pneumonia in adults. ( Breen, JD; Camere, MA; D'Ignazio, J; Jorgensen, D; Lewis, DE, 2005) |
| "This subgroup analysis sought to determine the efficacy and tolerability of a 5-day regimen of levofloxacin 750 mg/d compared with a 10-day regimen of levofloxacin 500 mg/d in the treatment of community-acquired pneumonia (CAP) in elderly patients (aged > or =65 years)." | 5.11 | A multicenter, randomized, double-blind, retrospective comparison of 5- and 10-day regimens of levofloxacin in a subgroup of patients aged > or =65 years with community-acquired pneumonia. ( Shorr, AF; Tennenberg, AM; Wes Ely, E; Xiang, JX; Zadeikis, N, 2005) |
| "In this study, we analyzed 302 patients with pneumonia admitted to the Intensive Care Unit (ICU) who were treated with levofloxacin (LFX) either as monotherapy or combined therapy." | 5.11 | Levofloxacin in the treatment of pneumonia in intensive care unit patients. ( Alvarez-Lerma, F; Bermejo, B; León, C; Olaechea, P; Palomar, M; Sanchez, M, 2004) |
| "Levofloxacin, an antibiotic from the quinolone family, which is used with success in the ambulatory treatment of patients with community-acquired pneumonia, has been recently introduced to the pharmaceutical market." | 5.09 | [Oral levofloxacin versus intravenous ceftriaxone and amoxicillin/clavulanic acid in the treatment of community-acquired pneumonia that requires hospitalization]. ( Bagilet, D; Diab, M; Javkin, E; Kalbermatter, V, 2000) |
| "Ofloxacin was used in the treatment of 24 patients with chronic bronchitis or pneumonia at the background of chronic bronchopulmonary and cardiovascular diseases." | 5.08 | [Clinical and pharmacokinetic evaluation of ofloxacin under various regimens of administration in patients with bronchopulmonary infections]. ( Belousov, OB; Efremenkova, OV; Gutkin, AB; Sokolov, AV; Tishchenkova, IF, 1996) |
| "Ofloxacin was used in the treatment of 15 patients (12 with pneumonia and 3 with aggravated chronic bronchitis)." | 5.08 | [Stepdown ofloxacin therapy in bronchopulmonary diseases]. ( Lenkova, NI; Makarova, OV; Nonikov, VE; Ritchik, LA, 1996) |
| "Our study of 28 carefully selected patients proved that ofloxacin is a safe and effective drug for mild to moderately severe community-acquired pneumonia." | 5.07 | Treatment of community-acquired pneumonia with ofloxacin. ( Charoenratanakul, S; Nana, A; Permpikul, C; Thamlikitkul, V; Youngchaiyud, P, 1991) |
| "The efficacy and safety of ofloxacin for the treatment of pneumonia, urinary infection and skin infections in the institutionalized elderly is being studied in a multicenter North American trial." | 5.07 | Ofloxacin use in a geriatric population. ( Alessi, P; Cullison, J; Degelau, J; Meyers, B; Nicolle, LE, 1991) |
| "To assess the safety and efficacy of a ten-day oral course of ofloxacin (400 mg 12 hourly) as compared with erythromycin (400 mg every 6 hours) for treatment of lower respiratory tract infections, fifty-two adult outpatients with pulmonary infiltrates (pneumonia) or with a cough and purulent sputum (bronchitis) were evaluated." | 5.07 | Treatment of lower respiratory infections in outpatients with ofloxacin compared with erythromycin. ( Hooton, TM; Lipsky, BA; Pecoraro, RE; Peugeot, RL, 1991) |
| "An exclusively oral regimen, in this case ofloxacin, may be substituted for parenteral therapy in selected patients with pneumonia." | 5.07 | Oral ofloxacin for the treatment of acute bacterial pneumonia: use of a nontraditional protocol to compare experimental therapy with "usual care" in a multicenter clinical trial. ( Alessi, P; Bittner, MJ; Iannini, P; Makris, AT; McCloskey, RV; Morris, JF; Sanders, WE; Trenholme, GM, 1991) |
| "Limited data suggest that tetracycline or erythromycin is the antibiotic of choice for treating Chlamydia pneumoniae infection, but they are not always effective or well tolerated." | 5.06 | Ofloxacin treatment of Chlamydia pneumoniae (strain TWAR) lower respiratory tract infections. ( Grayston, JT; Kuo, CC; Lipsky, BA; Tack, KJ; Wang, SP, 1990) |
| "Ofloxacin is highly active against common respiratory pathogens including Haemophilus influenzae and Branhamella catarrhalis and has clinically applicable activity against Streptococcus pneumoniae, Staphylococcus aureus and Pseudomonas aeruginosa." | 5.06 | Overview of experience with ofloxacin in respiratory tract infection. ( Ball, P, 1990) |
| "A randomized, open, prospective study including 45 patients with either soft tissue infections (29 cases) or pneumonia (15 cases) after surgical intervention and one case having both indications was carried out with ofloxacin." | 5.06 | Treatment of surgical infections with a modern quinolone: therapy of soft tissue infections and pneumonia with ofloxacin. ( Fritzen, T; Marx, E; Uy, J, 1986) |
| "In an open clinical trial, out-patients with respiratory tract infections were given 200 mg ofloxacin b." | 5.06 | [Respiratory tract infections--clinical results with ofloxacin]. ( Knothe, H; Shah, PM, 1986) |
| "The efficacy and tolerance of ofloxacin and doxycycline were compared in patients with lower respiratory tract infections." | 5.06 | An open randomised comparison of ofloxacin and doxycycline in lower respiratory tract infections. ( Harazim, H; Mittermayer, HP; Wimmer, J, 1987) |
| "Levofloxacin and sparfloxacin are active against pathogens frequently involved in community-acquired upper and lower respiratory tract infections, including Streptococcus pneumoniae, Haemophilus influenzae, Moraxella catarrhalis, Mycoplasma pneumoniae, Legionella pneumophila, and Chlamydia pneumoniae." | 4.80 | Levofloxacin and sparfloxacin: new quinolone antibiotics. ( Chuck, SK; Jung, R; Martin, SJ; Messick, CR; Meyer, JM; Pendland, SL, 1998) |
| "We describe four patients who had seizures while receiving ofloxacin; no other causes were evident." | 4.79 | Seizures associated with ofloxacin therapy. ( Bonfiglio, MF; Martin, BR; Nackes, NA; Traeger, SM; Wilson, JA, 1995) |
| "To evaluate the antibacterial and anti-inflammatory effects of kolaviron on albino Wistar rats induced with pneumonia using Klebsiella pneumonia." | 4.02 | Effects of Kolaviron on Pneumonia-like Infection Induced in Albino Wistar Rats. ( Catherine, OF; Dozie, NC; Dozie-Nwakile, OC; Felicia, ON; Kingsley, UI, 2021) |
| " holarctica in a stem cell transplant recipient with chronic graft-versus-host disease who was receiving levofloxacin prophylaxis." | 3.79 | Treatment of tularemia in patient with chronic graft-versus-host disease. ( Kaufmann, M; Knabbe, C; Seibold, E; Splettstoesser, W; Weile, J, 2013) |
| " We present a report of a 65-year-old woman with a bilateral Achilles tendon rupture following use of levofloxacin and corticosteroids for pneumonia." | 3.78 | [Bilateral Achilles tendon rupture following levofloxacin and glucocorticoid use]. ( Bénard, MR; Kok, LM; van Arkel, ER, 2012) |
| "CAP episodes were identified in the PharMetrics database between 2Q04 and 2Q07 based on: pneumonia diagnosis, chest X-ray and treatment with levofloxacin or moxifloxacin." | 3.76 | Hospital visits and costs following outpatient treatment of CAP with levofloxacin or moxifloxacin. ( Fisher, AC; Grant, R; Gu, A; Mody, SH; Ng, D; Raut, M; Schein, J; Sengupta, A; Sheng Duh, M; Signorovitch, JE, 2010) |
| "Levofloxacin (levogyre form of ofloxacin) has been approved for the treatment of acute and chronic sinusitis, pneumonia, and exacerbation of bronchopulmonary diseases, urinary, digestive and biliary infections in adults." | 3.76 | [Levofloxacin in children]. ( Cohen, R; Grimprel, E, 2010) |
| "We report an acute case of hepatitis following treatment with levofloxacin for pneumonia." | 3.76 | Acute hepatitis associated with the use of levofloxacin. ( Figueira-Coelho, J; Mendonça, P; Neta, J; Neves-Costa, J; Pereira, O; Picado, B, 2010) |
| "An 83-year-old man was admitted for right lower lobe pneumonia which did not improve after a 5-day outpatient treatment with amoxicillin/clavulinate and clarithromycin." | 3.75 | Levofloxacin-induced delirium. ( Elias, N; Odeh, M; Sabetay, S; Sheikh-Ahmad, M; Slobodin, G; Weller, B; Zaygraikin, N, 2009) |
| "A malnourished 58-year-old man with diabetes developed hypoglycemia after receiving levofloxacin in conjunction with glipizide." | 3.75 | Hypoglycemia associated with the use of levofloxacin. ( Garber, SM; Miller, SM; Pound, MW, 2009) |
| "In vitro evidence of synergy between glycopeptides, fluoroquinolones (levofloxacin) and beta-lactams and of reduction of mutational frequencies by combinations are suggestive for a potential role in empirical therapy of severe pneumonia with suspected MRSA etiology." | 3.74 | In vitro evaluation of antibiotics' combinations for empirical therapy of suspected methicillin resistant Staphylococcus aureus severe respiratory infections. ( De Vecchi, E; Drago, L; Gismondo, MR; Nicola, L, 2007) |
| "A pharmacodynamic model was used to generate supportive data comparing tigecycline with other broad-spectrum agents against pathogens implicated in hospital-acquired pneumonia (HAP)." | 3.74 | A pharmacodynamic simulation to assess tigecycline efficacy for hospital-acquired pneumonia compared with other common intravenous antibiotics. ( Dowzicky, M; Kuti, JL; Nicolau, DP, 2008) |
| "We describe the first case of failure of oral levofloxacin treatment of community-acquired pneumonia caused by Haemophilus influenzae." | 3.72 | Levofloxacin treatment failure in Haemophilus influenzae pneumonia. ( Alonso-Tarrés, C; Bastida, T; Campos, J; Cortés-Lletget, MC; de la Campa, AG; Pérez-Vázquez, M; Román, F; Tubau, F, 2003) |
| "THE EFFICACY OF LEVOFLOXACIN: In treating community-acquired pneumonia (CAP) has been assessed during 5 large clinical trials (including 4 controlled randomized trials)." | 3.71 | [Update on the role of levofloxacin in the management of acute community-acquired pneumonia]. ( Bru, JP, 2002) |
| "The aim of this study was to assess the clinical efficacy of a combination of penicillin G and ofloxacin in the treatment of community acquired pneumonia." | 3.68 | [The combination of penicillin G and ofloxacin: a response to the empirical treatment of community acquired pneumonia]. ( Canton, P; Dopff, C; Dureux, JB; Gerard, A; May, T; Mertes, PM; Nace, L; Preiss, MA; Voiriot, P, 1990) |
| "Ofloxacine (Tarivid-Hoechst) was used in 30 patients with infections of the respiratory system, including 12 with pneumonias, 18 with chronic bronchitis." | 3.68 | [Evaluation of the effectiveness of ofloxacin in the treatment of respiratory tract]. ( Chyrek-Borowska, S; Jakubicz, P; Siergiejko, Z, 1991) |
| "Ofloxacin (OFLX) or Enoxacin (ENX) was intramuscularly administered at a dose of 100 mg/kg to rats (normal and pneumonia model)." | 3.68 | [The penetration of ofloxacin and enoxacin into the alveolar spaces in rats]. ( Hayashi, Y; Ito, G; Kato, M; Takeuchi, T; Tashiro, T; Yamada, Y; Yamamoto, K; Yoshitomo, K, 1990) |
| "In order to determine the efficacy and safety of the new quinolone ofloxacin in the treatment of chronic lower respiratory disease, 674 patients (353 with chronic bronchitis, 212 with community-acquired pneumonia and 109 with hospital-acquired pneumonia) were treated with ofloxacin 200 mg twice a day." | 3.68 | Ofloxacin in lower respiratory tract infections. ( Petermann, W, 1991) |
| "We have compared the efficacy of temafloxacin against Streptococcus pneumoniae in experimental murine pneumonia models with that of ofloxacin and ciprofloxacin." | 3.68 | Comparative activity of fluorinated quinolones in acute and subacute Streptococcus pneumoniae pneumonia models: efficacy of temafloxacin. ( Azoulay-Dupuis, E; Bedos, JP; Pocidalo, JJ; Vallée, E, 1991) |
| "We report a multicentric, open trial of intravenous followed by oral ofloxacin, 400 mg every 12 h, as therapy for 100 cases of nosocomial pneumonia and community-acquired pneumonia requiring hospitalization." | 3.68 | Parenteral followed by oral ofloxacin for nosocomial pneumonia and community-acquired pneumonia requiring hospitalization. ( Gentry, LO; Khan, FA; Kohler, RB; Rodriguez-Gomez, G; Rytel, MW, 1992) |
| "A murine model of bacteremic Haemophilus influenzae type b pneumonia was used to evaluate the therapeutic efficacies of the quinolone antimicrobial agents enoxacin and ofloxacin compared with those of ampicillin and chloramphenicol." | 3.67 | Comparative evaluation of enoxacin, ofloxacin, ampicillin, and chloramphenicol for treatment of experimental Haemophilus influenzae pneumonia. ( Borner, K; Kemmerich, B; Pennington, JE, 1987) |
| "The chemotherapeutic efficacy of ofloxacin against experimental pneumonia was investigated with special reference to its treatment regimen." | 3.67 | Chemotherapeutic efficacy of ofloxacin against experimental pneumonia with Pseudomonas aeruginosa in guinea pigs. ( Hashimoto, S; Iigo, Y; Ishida, Y; Nakajima, R; Osada, Y; Otani, T; Une, T, 1989) |
| "The therapeutic activity of ciprofloxacin, enoxacin, and ofloxacin was evaluated in guinea pigs with acute and chronic experimental Pseudomonas aeruginosa pneumonia." | 3.67 | Comparative evaluation of ciprofloxacin, enoxacin, and ofloxacin in experimental Pseudomonas aeruginosa pneumonia. ( Kemmerich, B; Pennington, JE; Small, GJ, 1986) |
| "The clinical efficacy and the safety of ofloxacin in lower respiratory tract infections were evaluated by 42 research groups in Japan." | 3.67 | Clinical evaluation of ofloxacin in lower respiratory tract infections. ( Kobayashi, H, 1986) |
| "Levofloxacin was as well tolerated as azithromycin, with an incidence of drug-related adverse events (AEs) for all body systems of 5." | 2.70 | A multicenter, open-label, randomized comparison of levofloxacin and azithromycin plus ceftriaxone in hospitalized adults with moderate to severe community-acquired pneumonia. ( Bahal, N; Frank, E; Freitag, S; Kahn, JB; Kinasewitz, G; Liu, J; Moran, GJ; Olson, WH; Oross, MP; Reichl, V; Tennenberg, A; Wiesinger, BA, 2002) |
| " Dosage adjustment was made for patients in renal failure." | 2.67 | Efficacy of intravenous ofloxacin: a French multicentre trial in 185 patients. ( Beaucaire, G; Beuscart, C; Chidiac, C; Leroy, O; Mouton, Y; Senneville, E; Sivery, B; Vincent du Laurier, M, 1990) |
| "Ofloxacin was found to be a safe, well-tolerated therapeutic agent, which was as effective clinically as amoxicillin or erythromycin and with an advantage of less frequent administration." | 2.66 | Ofloxacin in community-acquired lower respiratory infections. A comparison with amoxicillin or erythromycin. ( Garcia, JG; Griffith, DE; Kohler, RB; Stocks, JM; Wallace, RJ, 1989) |
| "Ofloxacin was used without randomization in the treatment of 26 atypical pneumonias and opportunistic infections, all of which were cured or improved." | 2.66 | [Effect and tolerance of ofloxacin in bronchopulmonary infections in comparison with amoxicillin]. ( Chuard, C; Regamey, C, 1989) |
| "We present a case of a patient with hairy cell leukemia and pulmonary aspergillosis who developed a cycotic pulmonary artery aneurysm despite prolonged antifungal therapy." | 2.46 | Mycotic pulmonary artery aneurysm due to Aspergillus infection in a patient with leukemia: case report and review of the literature. ( Erasmus, J; Mattiuzzi, GN; Sever, M; Verstovsek, S, 2010) |
| "Levofloxacin (Levaquin) is a fluoroquinolone antibacterial that is the L-isomer of ofloxacin." | 2.44 | Levofloxacin : a review of its use as a high-dose, short-course treatment for bacterial infection. ( Anderson, VR; Perry, CM, 2008) |
| " Adherence to the prescribed regimen is affected by a number of variables including dosing interval, treatment duration, adverse effects, and palatability in pediatric patients." | 2.43 | Value of short-course antimicrobial therapy in community-acquired pneumonia. ( Blasi, F; Tarsia, P, 2005) |
| "Levofloxacin has been evaluated for the treatment of community-acquired pneumonia (CAP) in numerous randomized clinical trials." | 2.43 | Levofloxacin for the treatment of community-acquired pneumonia. ( File, TM; Lynch, JP; Zhanel, GG, 2006) |
| " Nine patients (2 with liver dysfunction, 6 with renal dysfunction and 1 with thrombocytopenia) out of 62 patients were reported to have possible adverse effects of LVFX." | 1.40 | [Efficacy and safety of levofloxacin in patients with nursing and healthcare-associated pneumonia]. ( Akata, K; Awaya, Y; Chojin, Y; Hara, K; Hata, R; Inoue, N; Ishimoto, H; Kato, K; Kawanami, T; Kawanami, Y; Mukae, H; Naito, K; Nishida, C; Noguchi, S; Obata, H; Oda, K; Ogoshi, T; Orihashi, T; Sasahara, Y; Shimabukuro, I; Shiraishi, T; Suzuki, Y; Tachiwada, T; Takaki, T; Taura, Y; Tokuyama, S; Tsuda, T; Uchimura, K; Yamasaki, K; Yatera, K; Yoshida, Y; Yoshii, C, 2014) |
| "Levofloxacin is a third-generation fluorinated quinolone antibiotic, is the active levo stereoisomer of ofloxacin, and has one of the most favorable adverse reaction profiles." | 1.38 | Levofloxacin-induced delirium: is it a dangerous drug in patients with renal dysfunction? ( Dortdudak, S; Eroglu, E; Kocyigit, I; Oymak, O; Sipahioglu, M; Tokgoz, B; Unal, A; Utas, C; Yucel, HE, 2012) |
| "Levofloxacin treatment did not affect the cytokine mRNA level and nuclear factor-κB-dependent promoter activity." | 1.37 | Levofloxacin reduces inflammatory cytokine levels in human bronchial epithelia cells: implications for aerosol MP-376 (levofloxacin solution for inhalation) treatment of chronic pulmonary infections. ( Dudley, MN; Griffith, DC; Lomovskaya, O; Sabet, M; Tarazi, Z; Tsivkovskii, R, 2011) |
| "Acute phlegmonous gastritis is an uncommon disease, often fatal condition characterized by suppurative bacterial infection of the gastric wall." | 1.37 | [A case of acute phlegmonous gastritis causing gastroparesis and cured with medical treatment alone]. ( Kim, JS; Kim, NY; Lee, KJ; Park, JS; Yun, HK, 2011) |
| "Levofloxacin was administered and 3 days later, he complained of pain in the left Achilles tendon and revealed redness and swelling in the area." | 1.36 | Levofloxacin-induced Achilles tendinitis in a young adult in the absence of predisposing conditions. ( Baek, YS; Cheong, MH; Durey, A; Lee, JS; Lee, K; Park, JS; Ryu, JS, 2010) |
| "Levofloxacin (500 mg) was administered intravenously, after surgery, in the ICU." | 1.35 | The impact of perioperative atelectasis on antibiotic penetration into lung tissue: an in vivo microdialysis study. ( Hutschala, D; Kinstner, C; Mayer-Helm, BX; Müller, M; Skhirtladze, K; Tschernko, E; Wisser, W; Zeitlinger, M, 2008) |
| "We suspected drug-induced pneumonitis, because her history of fever seemed to be related to drug administration for sinusitis." | 1.33 | [A case of drug-induced pneumonitis due to levofloxacin and kampo medicine]. ( Arakaki, N; Shimoji, T; Tamaki, K; Tohyama, M, 2006) |
| " The unbound AUC/MIC ratio revealed that levofloxacin used in the described manner was borderline sufficient for the treatment of nosocomial pneumonia caused by Klebsiella pneumoniae and insufficient for the treatment of pneumonia caused by Pseudomonas aeruginosa, because the breakpoint of 30 to 40 for AUC/MIC could not be reached by the conventionally used dosage schema in our post-CS setting." | 1.33 | In vivo measurement of levofloxacin penetration into lung tissue after cardiac surgery. ( Burgmann, H; Hutschala, D; Jaksch, P; Mayer-Helm, BX; Müller, M; Skhirtladze, K; Tschernko, EM; Wisser, W; Wolner, E; Zuckermann, A, 2005) |
| "We describe two patients with systemic lupus erythematosus (SLE) who presented with fever, systemic upset and pulmonary infiltrates between April and June, 2003." | 1.32 | Lupus pneumonitis or severe acute respiratory syndrome? ( Mok, CC; Ying, KY, 2004) |
| " Average length of stay (LOS), hospital costs, death rate, age, and ratio of oral to intravenous dosage administration were analyzed." | 1.31 | Experiences at a large teaching hospital with levofloxacin for the treatment of community-acquired pneumonia. ( Clark, LC; Davis, CW, 2000) |
| "Stevens-Johnson syndrome and toxic epidermal necrolysis (TEN) are mild-to-life-threatening adverse reactions that have been described after exposure to fluoroquinolones." | 1.31 | Levofloxacin-induced toxic epidermal necrolysis in an elderly patient. ( Ackerman, BH; Cawley, MJ; Digwood-Lettieri, S; Guilday, RJ; Haith, LR; Patton, ML; Reilly, KJ, 2002) |
| "The ofloxacin MICs were inoculum dependent and ranged from 0." | 1.27 | Susceptibility of Legionella pneumophila to ofloxacin in vitro and in experimental Legionella pneumonia in guinea pigs. ( Fujita, K; Fukuda, Y; Koga, H; Nagasawa, M; Nakazato, H; Saito, A; Sawatari, K; Shigeno, Y; Suzuyama, Y; Tomonaga, A, 1985) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 15 (14.42) | 18.7374 |
| 1990's | 25 (24.04) | 18.2507 |
| 2000's | 48 (46.15) | 29.6817 |
| 2010's | 15 (14.42) | 24.3611 |
| 2020's | 1 (0.96) | 2.80 |
| Authors | Studies |
|---|---|
| Dozie-Nwakile, OC | 1 |
| Dozie, NC | 1 |
| Kingsley, UI | 1 |
| Catherine, OF | 1 |
| Felicia, ON | 1 |
| Rice, DA | 1 |
| Kaniga, K | 1 |
| Lee, M | 1 |
| Redman, R | 1 |
| Weile, J | 1 |
| Seibold, E | 1 |
| Knabbe, C | 1 |
| Kaufmann, M | 1 |
| Splettstoesser, W | 1 |
| Yamasaki, K | 1 |
| Yatera, K | 1 |
| Kawanami, T | 1 |
| Sasahara, Y | 1 |
| Hata, R | 1 |
| Uchimura, K | 1 |
| Tachiwada, T | 1 |
| Naito, K | 1 |
| Kato, K | 1 |
| Takaki, T | 1 |
| Shimabukuro, I | 1 |
| Shiraishi, T | 1 |
| Oda, K | 1 |
| Hara, K | 1 |
| Chojin, Y | 1 |
| Suzuki, Y | 1 |
| Akata, K | 1 |
| Ogoshi, T | 1 |
| Tokuyama, S | 1 |
| Inoue, N | 1 |
| Noguchi, S | 1 |
| Nishida, C | 1 |
| Orihashi, T | 1 |
| Yoshida, Y | 1 |
| Kawanami, Y | 1 |
| Taura, Y | 1 |
| Ishimoto, H | 1 |
| Obata, H | 1 |
| Awaya, Y | 1 |
| Tsuda, T | 1 |
| Yoshii, C | 1 |
| Mukae, H | 1 |
| Slobodin, G | 1 |
| Elias, N | 1 |
| Zaygraikin, N | 1 |
| Sheikh-Ahmad, M | 1 |
| Sabetay, S | 1 |
| Weller, B | 1 |
| Odeh, M | 1 |
| Frei, CR | 1 |
| Jaso, TC | 1 |
| Mortensen, EM | 1 |
| Restrepo, MI | 1 |
| Raut, MK | 1 |
| Oramasionwu, CU | 1 |
| Ruiz, AD | 1 |
| Makos, BR | 1 |
| Ruiz, JL | 1 |
| Attridge, RT | 1 |
| Mody, SH | 2 |
| Fisher, A | 1 |
| Schein, JR | 1 |
| Zhang, X | 1 |
| Sun, P | 1 |
| Bi, R | 1 |
| Wang, J | 1 |
| Zhang, N | 1 |
| Huang, G | 1 |
| Louie, A | 1 |
| Fregeau, C | 1 |
| Liu, W | 1 |
| Kulawy, R | 1 |
| Drusano, GL | 1 |
| Garber, SM | 1 |
| Pound, MW | 1 |
| Miller, SM | 1 |
| Signorovitch, JE | 1 |
| Sheng Duh, M | 1 |
| Sengupta, A | 1 |
| Gu, A | 1 |
| Grant, R | 1 |
| Raut, M | 1 |
| Schein, J | 1 |
| Fisher, AC | 1 |
| Ng, D | 1 |
| Sever, M | 1 |
| Verstovsek, S | 1 |
| Erasmus, J | 1 |
| Mattiuzzi, GN | 1 |
| Durey, A | 1 |
| Baek, YS | 1 |
| Park, JS | 2 |
| Lee, K | 1 |
| Ryu, JS | 1 |
| Lee, JS | 1 |
| Cheong, MH | 1 |
| van Rensburg, DJ | 1 |
| Perng, RP | 1 |
| Mitha, IH | 1 |
| Bester, AJ | 1 |
| Kasumba, J | 1 |
| Wu, RG | 1 |
| Ho, ML | 1 |
| Chang, LW | 1 |
| Chung, DT | 1 |
| Chang, YT | 1 |
| King, CH | 1 |
| Hsu, MC | 1 |
| Grimprel, E | 1 |
| Cohen, R | 1 |
| Tsivkovskii, R | 1 |
| Sabet, M | 1 |
| Tarazi, Z | 1 |
| Griffith, DC | 1 |
| Lomovskaya, O | 1 |
| Dudley, MN | 1 |
| Figueira-Coelho, J | 1 |
| Pereira, O | 1 |
| Picado, B | 1 |
| Mendonça, P | 1 |
| Neves-Costa, J | 1 |
| Neta, J | 1 |
| Kim, NY | 1 |
| Lee, KJ | 1 |
| Yun, HK | 1 |
| Kim, JS | 1 |
| Guchev, IA | 1 |
| Melekhina, EV | 1 |
| Iudenich, OV | 1 |
| Kocyigit, I | 1 |
| Dortdudak, S | 1 |
| Sipahioglu, M | 1 |
| Unal, A | 1 |
| Yucel, HE | 1 |
| Tokgoz, B | 1 |
| Eroglu, E | 1 |
| Oymak, O | 1 |
| Utas, C | 1 |
| Kok, LM | 1 |
| Bénard, MR | 1 |
| van Arkel, ER | 1 |
| Gharabaghi, MA | 1 |
| Abdollahi, SM | 1 |
| Safavi, E | 1 |
| Abtahi, SH | 1 |
| Bru, JP | 1 |
| Frank, E | 1 |
| Liu, J | 1 |
| Kinasewitz, G | 1 |
| Moran, GJ | 1 |
| Oross, MP | 1 |
| Olson, WH | 1 |
| Reichl, V | 1 |
| Freitag, S | 1 |
| Bahal, N | 1 |
| Wiesinger, BA | 2 |
| Tennenberg, A | 1 |
| Kahn, JB | 3 |
| Bellmann, R | 1 |
| Egger, P | 1 |
| Pechlaner, C | 1 |
| Feistritzer, C | 1 |
| Vogel, W | 1 |
| Joannidis, M | 1 |
| Wiedermann, CJ | 1 |
| Dunbar, LM | 1 |
| Wunderink, RG | 1 |
| Habib, MP | 1 |
| Smith, LG | 1 |
| Tennenberg, AM | 2 |
| Khashab, MM | 1 |
| Xiang, JX | 2 |
| Zadeikis, N | 2 |
| Bastida, T | 1 |
| Pérez-Vázquez, M | 1 |
| Campos, J | 1 |
| Cortés-Lletget, MC | 1 |
| Román, F | 1 |
| Tubau, F | 1 |
| de la Campa, AG | 1 |
| Alonso-Tarrés, C | 1 |
| Marrie, TJ | 3 |
| Mok, CC | 1 |
| Ying, KY | 1 |
| Hoepelman, I | 1 |
| Alvarez-Lerma, F | 1 |
| Palomar, M | 1 |
| Olaechea, P | 1 |
| León, C | 1 |
| Sanchez, M | 1 |
| Bermejo, B | 1 |
| D'Ignazio, J | 1 |
| Camere, MA | 1 |
| Lewis, DE | 1 |
| Jorgensen, D | 1 |
| Breen, JD | 1 |
| Shorr, AF | 1 |
| Wes Ely, E | 1 |
| Hutschala, D | 2 |
| Skhirtladze, K | 2 |
| Zuckermann, A | 1 |
| Wisser, W | 2 |
| Jaksch, P | 1 |
| Mayer-Helm, BX | 2 |
| Burgmann, H | 1 |
| Wolner, E | 1 |
| Müller, M | 2 |
| Tschernko, EM | 1 |
| Pavié G, J | 1 |
| Prida C, JM | 1 |
| Díaz F, A | 1 |
| Saldías P, F | 1 |
| Blasi, F | 1 |
| Tarsia, P | 1 |
| Esposito, S | 1 |
| Noviello, S | 1 |
| Leone, S | 1 |
| Ianniello, F | 1 |
| Ascione, T | 1 |
| Gaeta, GB | 1 |
| Gibbons, FK | 1 |
| Branda, JA | 1 |
| Shepard, JA | 1 |
| Wang, S | 1 |
| Rizvi, AA | 1 |
| Kanbay, M | 1 |
| Aydogan, T | 1 |
| Bozalan, R | 1 |
| Isik, A | 1 |
| Uz, B | 1 |
| Kaya, A | 1 |
| Akcay, A | 1 |
| Lynch, JP | 1 |
| File, TM | 3 |
| Zhanel, GG | 1 |
| Tohyama, M | 1 |
| Arakaki, N | 1 |
| Tamaki, K | 1 |
| Shimoji, T | 1 |
| Ozkan, S | 1 |
| Akay, T | 1 |
| Drago, L | 1 |
| De Vecchi, E | 1 |
| Nicola, L | 1 |
| Gismondo, MR | 1 |
| Bradley, JS | 1 |
| Arguedas, A | 1 |
| Blumer, JL | 1 |
| Sáez-Llorens, X | 1 |
| Melkote, R | 1 |
| Noel, GJ | 1 |
| Anderson, VR | 1 |
| Perry, CM | 1 |
| Kuti, JL | 1 |
| Dowzicky, M | 1 |
| Nicolau, DP | 1 |
| Kinstner, C | 1 |
| Zeitlinger, M | 1 |
| Tschernko, E | 1 |
| Kobayashi, H | 2 |
| Takamura, K | 1 |
| Kono, K | 1 |
| Onodera, S | 1 |
| Sasaki, N | 1 |
| Nagahama, F | 1 |
| Kawakami, Y | 1 |
| Honma, Y | 1 |
| Matsuzaki, M | 1 |
| Tanimura, K | 1 |
| Plouffe, JF | 1 |
| Herbert, MT | 1 |
| Baird, I | 1 |
| Parsons, JN | 1 |
| Rielly-Gauvin, KT | 1 |
| Traeger, SM | 1 |
| Bonfiglio, MF | 1 |
| Wilson, JA | 1 |
| Martin, BR | 1 |
| Nackes, NA | 1 |
| Belousov, OB | 1 |
| Gutkin, AB | 1 |
| Sokolov, AV | 1 |
| Tishchenkova, IF | 1 |
| Efremenkova, OV | 1 |
| Nonikov, VE | 1 |
| Lenkova, NI | 1 |
| Makarova, OV | 1 |
| Ritchik, LA | 1 |
| Ambrose, PG | 1 |
| Owens, RC | 1 |
| Quintiliani, R | 1 |
| Nightingale, CH | 1 |
| Martin, SJ | 1 |
| Meyer, JM | 1 |
| Chuck, SK | 1 |
| Jung, R | 1 |
| Messick, CR | 1 |
| Pendland, SL | 1 |
| Weber, C | 1 |
| Maas, R | 1 |
| Steiner, P | 1 |
| Kramer, J | 1 |
| Bumann, D | 1 |
| Zander, AR | 1 |
| Bücheler, E | 1 |
| Fujita, A | 1 |
| Miya, T | 1 |
| Tanaka, R | 1 |
| Hirayama, S | 1 |
| Isaka, H | 1 |
| Ono, Y | 1 |
| Koshiishi, Y | 1 |
| Goya, T | 1 |
| Lau, CY | 1 |
| Wheeler, SL | 1 |
| Wong, CJ | 1 |
| Vandervoort, MK | 1 |
| Feagan, BG | 3 |
| Palmer, CS | 1 |
| Zhan, C | 1 |
| Elixhauser, A | 1 |
| Halpern, MT | 1 |
| Rance, L | 1 |
| Cunha, BA | 1 |
| Douadi, Y | 1 |
| Lescure, X | 1 |
| Schmit, JL | 1 |
| KiaNoury, D | 1 |
| Timpone, J | 1 |
| Yeager, H | 1 |
| Clark, LC | 1 |
| Davis, CW | 1 |
| Halley, HJ | 1 |
| Kalbermatter, V | 1 |
| Bagilet, D | 1 |
| Diab, M | 1 |
| Javkin, E | 1 |
| Milkovich, G | 1 |
| Carbon, C | 1 |
| Nuño Mateo, FJ | 1 |
| Noval Menéndez, J | 1 |
| Suárez, M | 1 |
| Guinea, O | 1 |
| Di Perna, CD | 1 |
| Vanni, S | 1 |
| Allegri, L | 1 |
| Manganelli, P | 1 |
| Buzio, C | 1 |
| Digwood-Lettieri, S | 1 |
| Reilly, KJ | 1 |
| Haith, LR | 1 |
| Patton, ML | 1 |
| Guilday, RJ | 1 |
| Cawley, MJ | 1 |
| Ackerman, BH | 1 |
| Gotfried, MH | 1 |
| Dattani, D | 1 |
| Riffer, E | 1 |
| Devcich, KJ | 1 |
| Busman, TA | 1 |
| Notario, GF | 1 |
| Palmer, RN | 1 |
| Azoulay-Dupuis, E | 1 |
| Bedos, JP | 1 |
| Vallée, E | 1 |
| Pocidalo, JJ | 1 |
| Gentry, LO | 1 |
| Rodriguez-Gomez, G | 1 |
| Kohler, RB | 3 |
| Khan, FA | 1 |
| Rytel, MW | 1 |
| Peugeot, RL | 1 |
| Lipsky, BA | 2 |
| Hooton, TM | 1 |
| Pecoraro, RE | 1 |
| Petermann, W | 1 |
| Chyrek-Borowska, S | 1 |
| Siergiejko, Z | 1 |
| Jakubicz, P | 1 |
| Thys, JP | 1 |
| Jacobs, F | 1 |
| Byl, B | 1 |
| Sanders, WE | 1 |
| Morris, JF | 1 |
| Alessi, P | 2 |
| Makris, AT | 1 |
| McCloskey, RV | 1 |
| Trenholme, GM | 1 |
| Iannini, P | 1 |
| Bittner, MJ | 1 |
| Arkins, N | 1 |
| Tack, KJ | 2 |
| Nicolle, LE | 1 |
| Degelau, J | 1 |
| Cullison, J | 1 |
| Meyers, B | 1 |
| Youngchaiyud, P | 1 |
| Permpikul, C | 1 |
| Thamlikitkul, V | 1 |
| Charoenratanakul, S | 1 |
| Nana, A | 1 |
| Lode, H | 1 |
| Wiley, E | 1 |
| Olschewski, P | 1 |
| Sievers, H | 1 |
| Wintermantel, M | 1 |
| Baetz, R | 1 |
| Lebahn, K | 1 |
| Reinke, M | 1 |
| Wagner, J | 1 |
| Borner, K | 2 |
| Ball, P | 1 |
| Kuo, CC | 1 |
| Wang, SP | 1 |
| Grayston, JT | 1 |
| Kato, M | 2 |
| Tashiro, T | 1 |
| Yoshitomo, K | 1 |
| Hayashi, Y | 2 |
| Ito, G | 2 |
| Yamamoto, K | 2 |
| Yamada, Y | 2 |
| Takeuchi, T | 2 |
| Mouton, Y | 1 |
| Leroy, O | 1 |
| Beuscart, C | 1 |
| Sivery, B | 1 |
| Senneville, E | 1 |
| Chidiac, C | 1 |
| Beaucaire, G | 1 |
| Vincent du Laurier, M | 1 |
| Dopff, C | 1 |
| Mertes, PM | 1 |
| Nace, L | 1 |
| Gerard, A | 1 |
| Voiriot, P | 1 |
| Preiss, MA | 1 |
| May, T | 1 |
| Canton, P | 1 |
| Dureux, JB | 1 |
| Kuroki, H | 1 |
| Matsuura, T | 1 |
| Fujioka, T | 1 |
| Miyake, T | 1 |
| Stocks, JM | 1 |
| Wallace, RJ | 1 |
| Griffith, DE | 1 |
| Garcia, JG | 1 |
| Chuard, C | 1 |
| Regamey, C | 1 |
| Otani, T | 1 |
| Nakajima, R | 1 |
| Hashimoto, S | 1 |
| Iigo, Y | 1 |
| Ishida, Y | 1 |
| Une, T | 1 |
| Osada, Y | 1 |
| Klesel, N | 1 |
| Limbert, M | 1 |
| Seibert, G | 1 |
| Winkler, I | 1 |
| Schrinner, E | 1 |
| Kemmerich, B | 2 |
| Small, GJ | 1 |
| Pennington, JE | 2 |
| Hirai, K | 1 |
| Aoyama, H | 1 |
| Hosaka, M | 1 |
| Oomori, Y | 1 |
| Niwata, Y | 1 |
| Suzue, S | 1 |
| Irikura, T | 1 |
| Delia, S | 1 |
| De Simone, C | 1 |
| Vullo, V | 1 |
| Sorice, F | 1 |
| Harazim, H | 1 |
| Wimmer, J | 1 |
| Mittermayer, HP | 1 |
| Shah, PM | 1 |
| Knothe, H | 1 |
| Fritzen, T | 1 |
| Marx, E | 1 |
| Uy, J | 1 |
| Saito, A | 1 |
| Sawatari, K | 1 |
| Fukuda, Y | 1 |
| Nagasawa, M | 1 |
| Koga, H | 1 |
| Tomonaga, A | 1 |
| Nakazato, H | 1 |
| Fujita, K | 1 |
| Shigeno, Y | 1 |
| Suzuyama, Y | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Retrospective, Real-world Study of Eucalyptol, Limonene and Pinene Enteric Soft Capsules Used in the Expectorant Treatment of Community-acquired Pneumonia[NCT05002192] | 10,000 participants (Anticipated) | Observational | 2020-09-01 | Recruiting | |||
| Multicenter, Double-Blind Randomized Study to Compare the Safety and Efficacy of Levofloxacin 750 mg Once Daily for Five Days vs. Levofloxacin 500 mg Once Daily for 10 Days in the Treatment of Mild to Severe Community-Acquired Pneumonia in Adults[NCT00236821] | Phase 3 | 530 participants (Actual) | Interventional | 2001-03-31 | Completed | ||
| Shortened Antibiotic Treatment in Community-Acquired Pneumonia: A Nationwide Danish Randomized Controlled Trial[NCT04089787] | Phase 4 | 564 participants (Anticipated) | Interventional | 2019-09-18 | Recruiting | ||
| Statins for the Early Treatment of Sepsis[NCT00528580] | Phase 2 | 68 participants (Actual) | Interventional | 2008-02-29 | Terminated (stopped due to Inadequate recruitment) | ||
| Suitability of Antibiotic Treatment for Community-acquired Pneumonia[NCT01661920] | 602 participants (Actual) | Interventional | 2012-01-31 | Completed | |||
| A Multicenter, Randomized, Open-Label, Comparative Study to Compare the Efficacy and Safety of Levofloxacin and Standard of Care Therapy in the Treatment of Children With Community-Acquired Pneumonia in the Hospitalized or Outpatient Setting[NCT00034736] | Phase 3 | 691 participants (Actual) | Interventional | 2002-08-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Normalization of vital signs for each subject enrolled. This is expressed as a mean time to normalization for each +/- standard error. (NCT00528580)
Timeframe: 24 hours
| Intervention | days (Mean) |
|---|---|
| Treatment Group | 3 |
| Control Group | 3 |
12 reviews available for ofloxacin and Pneumonia
| Article | Year |
|---|---|
Mycotic pulmonary artery aneurysm due to Aspergillus infection in a patient with leukemia: case report and review of the literature.
Topics: Abscess; Acyclovir; Amphotericin B; Aneurysm, Infected; Anti-Bacterial Agents; Antifungal Agents; An | 2010 |
[New fluoroquinolones: levofloxacin, moxifloxacin and gatifloxacin].
Topics: Anti-Bacterial Agents; Aza Compounds; Drug Resistance, Bacterial; Fluoroquinolones; Gatifloxacin; Gr | 2004 |
Value of short-course antimicrobial therapy in community-acquired pneumonia.
Topics: Anti-Bacterial Agents; Azithromycin; Clarithromycin; Clinical Trials, Phase III as Topic; Community- | 2005 |
Levofloxacin for the treatment of community-acquired pneumonia.
Topics: Community-Acquired Infections; Humans; Levofloxacin; Ofloxacin; Pneumonia | 2006 |
Levofloxacin : a review of its use as a high-dose, short-course treatment for bacterial infection.
Topics: Animals; Anti-Bacterial Agents; Bacterial Infections; Community-Acquired Infections; Drug Resistance | 2008 |
Seizures associated with ofloxacin therapy.
Topics: Aged; Aged, 80 and over; Female; Haemophilus Infections; Haemophilus influenzae; Humans; Klebsiella | 1995 |
New generations of quinolones: with particular attention to levofloxacin.
Topics: Anti-Infective Agents; Community-Acquired Infections; Fluoroquinolones; Humans; Levofloxacin; Ofloxa | 1997 |
Levofloxacin and sparfloxacin: new quinolone antibiotics.
Topics: Absorption; Anti-Infective Agents; Bronchitis; Drug Interactions; Drug Resistance, Microbial; Fluoro | 1998 |
Optimal treatment strategies for community-acquired pneumonia: non-responders to conventional regimens.
Topics: Anti-Infective Agents; Community-Acquired Infections; Drug Resistance, Microbial; Female; Humans; Ma | 2001 |
Optimal treatment strategies for community-acquired pneumonia: high-risk patients (geriatric and with comorbidity).
Topics: Age Factors; Aged; Anti-Infective Agents; Community-Acquired Infections; Comorbidity; Drug Resistanc | 2001 |
Severe glomerulonephritis and isolated ileitis in adult Henoch-Schoenlein purpura.
Topics: Anti-Infective Agents; Cyclophosphamide; Drug Therapy, Combination; Glomerulonephritis; Humans; IgA | 2001 |
Role of quinolones in the treatment of bronchopulmonary infections, particularly pneumococcal and community-acquired pneumonia.
Topics: Anti-Infective Agents; Bronchitis; Ciprofloxacin; Drug Therapy, Combination; Enoxacin; Humans; Oflox | 1991 |
32 trials available for ofloxacin and Pneumonia
| Article | Year |
|---|---|
Activity of doripenem versus comparators in subjects with baseline bacteraemia in six pooled phase 3 clinical trials.
Topics: Anti-Bacterial Agents; Bacteremia; Carbapenems; Cross Infection; Doripenem; Female; Humans; Imipenem | 2013 |
Efficacy and safety of nemonoxacin versus levofloxacin for community-acquired pneumonia.
Topics: Adult; Anti-Bacterial Agents; Double-Blind Method; Female; Humans; Levofloxacin; Male; Middle Aged; | 2010 |
A multicenter, open-label, randomized comparison of levofloxacin and azithromycin plus ceftriaxone in hospitalized adults with moderate to severe community-acquired pneumonia.
Topics: Adult; Aged; Aged, 80 and over; Azithromycin; Ceftriaxone; Community-Acquired Infections; Drug Thera | 2002 |
High-dose, short-course levofloxacin for community-acquired pneumonia: a new treatment paradigm.
Topics: Adult; Anti-Infective Agents; Community-Acquired Infections; Double-Blind Method; Female; Humans; Le | 2003 |
High-dose, short-course levofloxacin for community-acquired pneumonia: a new treatment paradigm.
Topics: Adult; Anti-Infective Agents; Community-Acquired Infections; Double-Blind Method; Female; Humans; Le | 2003 |
High-dose, short-course levofloxacin for community-acquired pneumonia: a new treatment paradigm.
Topics: Adult; Anti-Infective Agents; Community-Acquired Infections; Double-Blind Method; Female; Humans; Le | 2003 |
High-dose, short-course levofloxacin for community-acquired pneumonia: a new treatment paradigm.
Topics: Adult; Anti-Infective Agents; Community-Acquired Infections; Double-Blind Method; Female; Humans; Le | 2003 |
High-dose, short-course levofloxacin for community-acquired pneumonia: a new treatment paradigm.
Topics: Adult; Anti-Infective Agents; Community-Acquired Infections; Double-Blind Method; Female; Humans; Le | 2003 |
High-dose, short-course levofloxacin for community-acquired pneumonia: a new treatment paradigm.
Topics: Adult; Anti-Infective Agents; Community-Acquired Infections; Double-Blind Method; Female; Humans; Le | 2003 |
High-dose, short-course levofloxacin for community-acquired pneumonia: a new treatment paradigm.
Topics: Adult; Anti-Infective Agents; Community-Acquired Infections; Double-Blind Method; Female; Humans; Le | 2003 |
High-dose, short-course levofloxacin for community-acquired pneumonia: a new treatment paradigm.
Topics: Adult; Anti-Infective Agents; Community-Acquired Infections; Double-Blind Method; Female; Humans; Le | 2003 |
High-dose, short-course levofloxacin for community-acquired pneumonia: a new treatment paradigm.
Topics: Adult; Anti-Infective Agents; Community-Acquired Infections; Double-Blind Method; Female; Humans; Le | 2003 |
High-dose, short-course levofloxacin for community-acquired pneumonia: a new treatment paradigm.
Topics: Adult; Anti-Infective Agents; Community-Acquired Infections; Double-Blind Method; Female; Humans; Le | 2003 |
High-dose, short-course levofloxacin for community-acquired pneumonia: a new treatment paradigm.
Topics: Adult; Anti-Infective Agents; Community-Acquired Infections; Double-Blind Method; Female; Humans; Le | 2003 |
High-dose, short-course levofloxacin for community-acquired pneumonia: a new treatment paradigm.
Topics: Adult; Anti-Infective Agents; Community-Acquired Infections; Double-Blind Method; Female; Humans; Le | 2003 |
High-dose, short-course levofloxacin for community-acquired pneumonia: a new treatment paradigm.
Topics: Adult; Anti-Infective Agents; Community-Acquired Infections; Double-Blind Method; Female; Humans; Le | 2003 |
High-dose, short-course levofloxacin for community-acquired pneumonia: a new treatment paradigm.
Topics: Adult; Anti-Infective Agents; Community-Acquired Infections; Double-Blind Method; Female; Humans; Le | 2003 |
High-dose, short-course levofloxacin for community-acquired pneumonia: a new treatment paradigm.
Topics: Adult; Anti-Infective Agents; Community-Acquired Infections; Double-Blind Method; Female; Humans; Le | 2003 |
High-dose, short-course levofloxacin for community-acquired pneumonia: a new treatment paradigm.
Topics: Adult; Anti-Infective Agents; Community-Acquired Infections; Double-Blind Method; Female; Humans; Le | 2003 |
Experience with levofloxacin in a critical pathway for the treatment of community-acquired pneumonia.
Topics: Adolescent; Adult; Age Factors; Aged; Aged, 80 and over; Ambulatory Care; Anti-Infective Agents; Azi | 2004 |
Levofloxacin in the treatment of pneumonia in intensive care unit patients.
Topics: Adult; Aged; Anti-Bacterial Agents; Community-Acquired Infections; Critical Illness; Cross Infection | 2004 |
Novel, single-dose microsphere formulation of azithromycin versus 7-day levofloxacin therapy for treatment of mild to moderate community-acquired Pneumonia in adults.
Topics: Adult; Aged; Anti-Bacterial Agents; Azithromycin; Chemistry, Pharmaceutical; Community-Acquired Infe | 2005 |
A multicenter, randomized, double-blind, retrospective comparison of 5- and 10-day regimens of levofloxacin in a subgroup of patients aged > or =65 years with community-acquired pneumonia.
Topics: Aged; Aged, 80 and over; Anti-Bacterial Agents; Community-Acquired Infections; Double-Blind Method; | 2005 |
Comparative study of levofloxacin in the treatment of children with community-acquired pneumonia.
Topics: Adolescent; Amoxicillin-Potassium Clavulanate Combination; Anti-Bacterial Agents; Ceftriaxone; Child | 2007 |
[Comparison of DL-8280 and amoxicillin in the treatment of respiratory tract infections].
Topics: Adult; Aged; Amoxicillin; Anti-Infective Agents; Bronchiectasis; Bronchitis; Clinical Trials as Topi | 1984 |
Ofloxacin versus standard therapy in treatment of community-acquired pneumonia requiring hospitalization. Pneumonia Study Group.
Topics: Adolescent; Adult; Aged; Anti-Bacterial Agents; Anti-Infective Agents; Drug Therapy, Combination; Fe | 1996 |
[Clinical and pharmacokinetic evaluation of ofloxacin under various regimens of administration in patients with bronchopulmonary infections].
Topics: Administration, Oral; Anti-Infective Agents; Bronchitis; Cardiovascular Diseases; Drug Administratio | 1996 |
[Stepdown ofloxacin therapy in bronchopulmonary diseases].
Topics: Administration, Oral; Anti-Infective Agents; Bronchitis; Chronic Disease; Drug Administration Schedu | 1996 |
A controlled trial of a critical pathway for treatment of community-acquired pneumonia. CAPITAL Study Investigators. Community-Acquired Pneumonia Intervention Trial Assessing Levofloxacin.
Topics: Aged; Anti-Infective Agents; Canada; Community-Acquired Infections; Critical Pathways; Female; Hospi | 2000 |
Economic assessment of the community-acquired pneumonia intervention trial employing levofloxacin.
Topics: Aged; Anti-Infective Agents; Canada; Cluster Analysis; Community-Acquired Infections; Critical Pathw | 2000 |
[Oral levofloxacin versus intravenous ceftriaxone and amoxicillin/clavulanic acid in the treatment of community-acquired pneumonia that requires hospitalization].
Topics: Administration, Oral; Adult; Aged; Amoxicillin-Potassium Clavulanate Combination; Analysis of Varian | 2000 |
A controlled trial of a critical pathway for treating community-acquired pneumonia: the CAPITAL study. Community-Acquired Pneumonia Intervention Trial Assessing Levofloxacin.
Topics: Administration, Oral; Adult; Anti-Infective Agents; Canada; Community-Acquired Infections; Critical | 2001 |
A controlled, double-blind, multicenter study comparing clarithromycin extended-release tablets and levofloxacin tablets in the treatment of community-acquired pneumonia.
Topics: Adult; Aged; Anti-Bacterial Agents; Clarithromycin; Community-Acquired Infections; Delayed-Action Pr | 2002 |
Treatment of lower respiratory infections in outpatients with ofloxacin compared with erythromycin.
Topics: Adult; Aged; Bronchitis; Chlamydia Infections; Erythromycin; Female; Humans; Legionnaires' Disease; | 1991 |
Role of quinolones in the treatment of bronchopulmonary infections, particularly pneumococcal and community-acquired pneumonia.
Topics: Anti-Infective Agents; Bronchitis; Ciprofloxacin; Drug Therapy, Combination; Enoxacin; Humans; Oflox | 1991 |
Oral ofloxacin for the treatment of acute bacterial pneumonia: use of a nontraditional protocol to compare experimental therapy with "usual care" in a multicenter clinical trial.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Bacterial Infections; Female; Humans; Male; Mi | 1991 |
Ofloxacin use in a geriatric population.
Topics: Aged; Cross Infection; Gram-Negative Bacteria; Gram-Positive Bacteria; Humans; Ofloxacin; Pneumonia; | 1991 |
Treatment of community-acquired pneumonia with ofloxacin.
Topics: Administration, Oral; Adolescent; Adult; Aged; Bacterial Infections; Female; Humans; Male; Microbial | 1991 |
Prospective randomized clinical trials of new quinolones versus beta-lactam antibiotics in lower respiratory tract infections.
Topics: Cilastatin; Cilastatin, Imipenem Drug Combination; Ciprofloxacin; Clavulanic Acids; Drug Combination | 1990 |
Overview of experience with ofloxacin in respiratory tract infection.
Topics: Bronchitis; Chronic Disease; Humans; Ofloxacin; Pneumonia; Remission Induction; Respiratory Tract In | 1990 |
Ofloxacin treatment of Chlamydia pneumoniae (strain TWAR) lower respiratory tract infections.
Topics: Aged; Bronchitis; Chlamydia; Chlamydia Infections; Clinical Trials as Topic; Drug Resistance, Microb | 1990 |
Efficacy of intravenous ofloxacin: a French multicentre trial in 185 patients.
Topics: Administration, Oral; Adolescent; Adult; Aged; Aged, 80 and over; Bacterial Infections; Female; Fran | 1990 |
Ofloxacin in community-acquired lower respiratory infections. A comparison with amoxicillin or erythromycin.
Topics: Adult; Amoxicillin; Bronchitis; Erythromycin; Female; Humans; Lung Diseases, Obstructive; Male; Midd | 1989 |
[Effect and tolerance of ofloxacin in bronchopulmonary infections in comparison with amoxicillin].
Topics: Aged; Amoxicillin; Female; Humans; Male; Middle Aged; Multicenter Studies as Topic; Ofloxacin; Pneum | 1989 |
An open randomised comparison of ofloxacin and doxycycline in lower respiratory tract infections.
Topics: Anti-Infective Agents; Bronchitis; Chronic Disease; Doxycycline; Humans; Microbial Sensitivity Tests | 1987 |
[Respiratory tract infections--clinical results with ofloxacin].
Topics: Adult; Anti-Bacterial Agents; Bacterial Infections; Bronchitis; Chronic Disease; Clinical Trials as | 1986 |
Treatment of surgical infections with a modern quinolone: therapy of soft tissue infections and pneumonia with ofloxacin.
Topics: Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Bacterial Infections; Clinical Trials as Topi | 1986 |
61 other studies available for ofloxacin and Pneumonia
| Article | Year |
|---|---|
Effects of Kolaviron on Pneumonia-like Infection Induced in Albino Wistar Rats.
Topics: Animals; Anti-Bacterial Agents; Anti-Inflammatory Agents; Disease Models, Animal; Dose-Response Rela | 2021 |
Treatment of tularemia in patient with chronic graft-versus-host disease.
Topics: Anti-Bacterial Agents; Chronic Disease; Doxycycline; Francisella tularensis; Graft vs Host Disease; | 2013 |
[Efficacy and safety of levofloxacin in patients with nursing and healthcare-associated pneumonia].
Topics: Anti-Bacterial Agents; Cross Infection; Female; Humans; Japan; Levofloxacin; Male; Ofloxacin; Pneumo | 2014 |
Levofloxacin-induced delirium.
Topics: Age Factors; Aged, 80 and over; Amoxicillin; Anti-Bacterial Agents; beta-Lactams; Brain; Clarithromy | 2009 |
Medical resource utilization among community-acquired pneumonia patients initially treated with levofloxacin 750 mg daily versus ceftriaxone 1000 mg plus azithromycin 500 mg daily: a US-based study.
Topics: Adult; Aged; Anti-Bacterial Agents; Azithromycin; Ceftriaxone; Community-Acquired Infections; Drug T | 2009 |
Targeted delivery of levofloxacin-liposomes for the treatment of pulmonary inflammation.
Topics: Animals; Anti-Bacterial Agents; Area Under Curve; Chemistry, Pharmaceutical; Female; Levofloxacin; L | 2009 |
Pharmacodynamics of levofloxacin in a murine pneumonia model of Pseudomonas aeruginosa infection: determination of epithelial lining fluid targets.
Topics: Animals; Anti-Bacterial Agents; Bronchoalveolar Lavage Fluid; Disease Models, Animal; Epithelium; Fe | 2009 |
Hypoglycemia associated with the use of levofloxacin.
Topics: Anti-Bacterial Agents; Community-Acquired Infections; Diabetes Mellitus, Type 2; Drug Interactions; | 2009 |
Hospital visits and costs following outpatient treatment of CAP with levofloxacin or moxifloxacin.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Algorithms; Ambulatory Care; Anti-Infective Agents; Aza | 2010 |
Levofloxacin-induced Achilles tendinitis in a young adult in the absence of predisposing conditions.
Topics: Achilles Tendon; Adult; Anti-Bacterial Agents; Community-Acquired Infections; Disease Susceptibility | 2010 |
[Levofloxacin in children].
Topics: Adult; Anti-Bacterial Agents; Bacterial Infections; Child; Community-Acquired Infections; Humans; Le | 2010 |
Levofloxacin reduces inflammatory cytokine levels in human bronchial epithelia cells: implications for aerosol MP-376 (levofloxacin solution for inhalation) treatment of chronic pulmonary infections.
Topics: Administration, Inhalation; Aerosols; Anti-Inflammatory Agents; Cell Line; Chronic Disease; Epitheli | 2011 |
Acute hepatitis associated with the use of levofloxacin.
Topics: Acute Disease; Aged; Anti-Bacterial Agents; Biopsy, Needle; Chemical and Drug Induced Liver Injury; | 2010 |
[A case of acute phlegmonous gastritis causing gastroparesis and cured with medical treatment alone].
Topics: Acinetobacter; Acute Disease; Aged; Anti-Bacterial Agents; Anti-Infective Agents; Cefotaxime; Ceftri | 2011 |
[Levofloxacin. expediency of high-dose regimens in therapy of lower respiratory tract infections].
Topics: Community-Acquired Infections; Gram-Negative Bacteria; Gram-Positive Bacteria; Humans; Levofloxacin; | 2011 |
Levofloxacin-induced delirium: is it a dangerous drug in patients with renal dysfunction?
Topics: Anti-Bacterial Agents; Delirium; Follow-Up Studies; Humans; Levofloxacin; Magnetic Resonance Imaging | 2012 |
[Bilateral Achilles tendon rupture following levofloxacin and glucocorticoid use].
Topics: Achilles Tendon; Aged; Anti-Infective Agents; Casts, Surgical; Female; Glucocorticoids; Humans; Levo | 2012 |
Community acquired Pseudomonas pneumonia in an immune competent host.
Topics: Adult; Anti-Bacterial Agents; Biopsy; Community-Acquired Infections; Diagnosis, Differential; Humans | 2012 |
[Update on the role of levofloxacin in the management of acute community-acquired pneumonia].
Topics: Acute Disease; Anti-Infective Agents; Bacteremia; Community-Acquired Infections; Humans; Levofloxaci | 2002 |
Moxifloxacin: new preparation. A me-too with more cardiac risks.
Topics: Anti-Bacterial Agents; Anti-Infective Agents; Ciprofloxacin; Drug Approval; Fluoroquinolones; France | 2002 |
Levofloxacin elimination during albumin dialysis.
Topics: Adult; Albumins; Anti-Infective Agents; Crigler-Najjar Syndrome; Dialysis; Female; Humans; Levofloxa | 2003 |
Levofloxacin treatment failure in Haemophilus influenzae pneumonia.
Topics: Aged; Anti-Infective Agents; Community-Acquired Infections; DNA Gyrase; Electrophoresis, Gel, Pulsed | 2003 |
Lupus pneumonitis or severe acute respiratory syndrome?
Topics: Adult; Antiviral Agents; China; Community-Acquired Infections; Diagnosis, Differential; Female; Huma | 2004 |
In vivo measurement of levofloxacin penetration into lung tissue after cardiac surgery.
Topics: Aged; Anti-Infective Agents; Area Under Curve; Coronary Artery Bypass; Dose-Response Relationship, D | 2005 |
[Assessment of the management of community-acquired pneumonia in adults outpatients].
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Ambulatory Care; Amoxicillin; Anti-Bacterial Agents; Chi | 2005 |
Clinical efficacy and tolerability of levofloxacin in patients with liver disease: a prospective, non comparative, observational study.
Topics: Administration, Oral; Anti-Bacterial Agents; Chronic Disease; Drug Tolerance; Female; Humans; Levofl | 2006 |
Case records of the Massachusetts General Hospital. Case 12-2006. A 37-year-old man with hemoptysis and a pulmonary infiltrate.
Topics: Adult; Anti-Infective Agents; Diagnosis, Differential; Hemoptysis; Humans; Lung; Lung Neoplasms; Mal | 2006 |
Levofloxacin-induced hypoglycemia in a nondiabetic patient.
Topics: Aged; Anti-Bacterial Agents; Coronary Artery Bypass; Female; Glucagon; Glucose; Humans; Hypoglycemia | 2006 |
A Rare but serious side effect of Levofloxacin: hypoglycemia in a geriatric patient.
Topics: Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemia; Levofloxacin; Middle Aged; Ofloxacin; Pneum | 2006 |
[A case of drug-induced pneumonitis due to levofloxacin and kampo medicine].
Topics: Anti-Inflammatory Agents, Non-Steroidal; Drugs, Chinese Herbal; Female; Humans; Levofloxacin; Medici | 2006 |
Diaphragm paralysis in children after cardiac surgery.
Topics: Anti-Bacterial Agents; Cardiac Surgical Procedures; Cefazolin; Diaphragm; Female; Heart Defects, Con | 2007 |
In vitro evaluation of antibiotics' combinations for empirical therapy of suspected methicillin resistant Staphylococcus aureus severe respiratory infections.
Topics: Amikacin; Anti-Bacterial Agents; beta-Lactams; Drug Therapy, Combination; Humans; Levofloxacin; Meth | 2007 |
A pharmacodynamic simulation to assess tigecycline efficacy for hospital-acquired pneumonia compared with other common intravenous antibiotics.
Topics: Anti-Bacterial Agents; Cross Infection; Humans; Imipenem; Levofloxacin; Microbial Sensitivity Tests; | 2008 |
The impact of perioperative atelectasis on antibiotic penetration into lung tissue: an in vivo microdialysis study.
Topics: Adult; Aged; Anti-Bacterial Agents; Coronary Artery Bypass; Coronary Artery Bypass, Off-Pump; Humans | 2008 |
Sparfloxacin and levofloxacin.
Topics: Administration, Oral; Anti-Infective Agents; Bronchitis; Chronic Disease; Clinical Trials as Topic; | 1997 |
[Importance of digital thoracic radiography in the diagnosis of pulmonary infiltrates in patients with bone marrow transplantation during aplasia].
Topics: Adult; Anemia, Aplastic; Anti-Infective Agents; Antibiotic Prophylaxis; Antifungal Agents; Bone Marr | 1999 |
[Levofloxacin concentrations in serum, sputum and lung tissue: evaluation of its efficacy according to breakpoint].
Topics: Adult; Aged; Chronic Disease; Female; Humans; Levofloxacin; Lung; Male; Middle Aged; Ofloxacin; Pneu | 1999 |
Community-acquired pneumonia: reality revisited.
Topics: Anti-Bacterial Agents; Anti-Infective Agents; Community-Acquired Infections; Doxycycline; Gram-Negat | 2000 |
[A new antibiotic: levofloxacine].
Topics: Anti-Infective Agents; Bronchitis; Community-Acquired Infections; Humans; Ofloxacin; Pneumonia; Sinu | 2000 |
Can administration of a fluoroquinolone delay diagnosis of pulmonary tuberculosis?
Topics: Adult; Bronchoalveolar Lavage Fluid; Female; Humans; Mycobacterium tuberculosis; Ofloxacin; Pneumoni | 2000 |
Experiences at a large teaching hospital with levofloxacin for the treatment of community-acquired pneumonia.
Topics: Administration, Oral; Adolescent; Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Anti-Infect | 2000 |
Approaches to drug therapy, formulary, and pathway management in a large community hospital.
Topics: Administration, Oral; Anti-Bacterial Agents; Anti-Infective Agents; Bacteria; Community-Acquired Inf | 2000 |
Intravenous-to-oral transition therapy in community-acquired pneumonia: the INOVA Health System experience.
Topics: Administration, Oral; Aged; Anti-Infective Agents; APACHE; Ciprofloxacin; Community-Acquired Infecti | 2001 |
[Achilles pain and functional impotence in a patient with chronic obstructive pulmonary disease with pneumonia. Tendon rupture caused by levofloxacin].
Topics: Achilles Tendon; Aged; Anti-Infective Agents; Humans; Levofloxacin; Male; Ofloxacin; Pain; Pneumonia | 2001 |
Levofloxacin-induced toxic epidermal necrolysis in an elderly patient.
Topics: Aged; Anti-Infective Agents; Community-Acquired Infections; Female; Fluid Therapy; Humans; Levofloxa | 2002 |
Comparative activity of fluorinated quinolones in acute and subacute Streptococcus pneumoniae pneumonia models: efficacy of temafloxacin.
Topics: Acute Disease; Animals; Anti-Infective Agents; Disease Models, Animal; Female; Fluoroquinolones; Mic | 1991 |
Parenteral followed by oral ofloxacin for nosocomial pneumonia and community-acquired pneumonia requiring hospitalization.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Bacterial Infections; Cross Infection; Female; | 1992 |
Ofloxacin in lower respiratory tract infections.
Topics: Bacterial Infections; Bronchitis; Chronic Disease; Cross Infection; Drug Administration Schedule; Dr | 1991 |
[Evaluation of the effectiveness of ofloxacin in the treatment of respiratory tract].
Topics: Administration, Oral; Adult; Aged; Bronchitis; Chronic Disease; Drug Resistance, Microbial; Enteroco | 1991 |
Accidental overdose of intravenous ofloxacin with benign outcome.
Topics: Adult; Central Nervous System Diseases; Drug Overdose; Female; Humans; Injections, Intravenous; Oflo | 1991 |
[The penetration of ofloxacin and enoxacin into the alveolar spaces in rats].
Topics: Animals; Bronchoalveolar Lavage Fluid; Capillary Permeability; Enoxacin; Ofloxacin; Pneumonia; Pulmo | 1990 |
[The combination of penicillin G and ofloxacin: a response to the empirical treatment of community acquired pneumonia].
Topics: Acute Disease; Adolescent; Adult; Aged; Aged, 80 and over; Drug Administration Schedule; Drug Therap | 1990 |
[The clinical effectiveness of OFLX in the treatment of chlamydial pneumonia].
Topics: Adolescent; Adult; Child; Chlamydophila psittaci; Drug Resistance, Microbial; Female; Humans; Male; | 1989 |
Chemotherapeutic efficacy of ofloxacin against experimental pneumonia with Pseudomonas aeruginosa in guinea pigs.
Topics: Animals; Disease Models, Animal; Female; Guinea Pigs; Immunosuppression Therapy; Lung; Ofloxacin; Pn | 1989 |
Chemotherapeutic effects of ofloxacin (HOE 280) and other quinolone-carboxylic derivates in the treatment of experimental lung infections due to Klebsiella pneumoniae DT-S in mice.
Topics: Animals; Anti-Bacterial Agents; Ciprofloxacin; Dose-Response Relationship, Drug; Enoxacin; Klebsiell | 1986 |
Comparative evaluation of ciprofloxacin, enoxacin, and ofloxacin in experimental Pseudomonas aeruginosa pneumonia.
Topics: Animals; Anti-Infective Agents; Ciprofloxacin; Enoxacin; Guinea Pigs; Kinetics; Naphthyridines; Oflo | 1986 |
In vitro and in vivo antibacterial activity of AM-833, a new quinolone derivative.
Topics: Animals; Anti-Bacterial Agents; Bacteria; Bacterial Infections; Ciprofloxacin; Drug Resistance, Micr | 1986 |
Clinical evaluation of ofloxacin in lower respiratory tract infections.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Infective Agents; Chronic Disease; Female; Humans; | 1986 |
Ofloxacin: clinical evaluation in urinary and respiratory infections.
Topics: Adult; Aged; Anti-Infective Agents; Female; Humans; Male; Middle Aged; Ofloxacin; Oxazines; Pneumoni | 1986 |
Comparative evaluation of enoxacin, ofloxacin, ampicillin, and chloramphenicol for treatment of experimental Haemophilus influenzae pneumonia.
Topics: Ampicillin; Animals; Anti-Bacterial Agents; Chloramphenicol; Enoxacin; Female; Haemophilus Infection | 1987 |
Susceptibility of Legionella pneumophila to ofloxacin in vitro and in experimental Legionella pneumonia in guinea pigs.
Topics: Animals; Anti-Bacterial Agents; Bacterial Infections; Guinea Pigs; Humans; In Vitro Techniques; Legi | 1985 |